[12] Patent
[11] Patent No.:GC0007654  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126505
Date of the Decision to Grant the Patent:26/Apr/2018

[21] Application No.:GC 2011-19631

[22] Filing Date:29/10/2011

[72] Inventors:1- Catherine Leblanc،2- Steven John Charlton،3- Stephen Carl Mckeown

[73] Owner: Novartis AG, Lichtstrasse 35 4056, Basel , Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.7: [C07D471/04;A61K31/4375;A61P9/00;A61P11/00]

[56] Cited Documents:

-DRISCOLL J A ET AL: Medical therapy for pulmonary arterial hypertension, EXPERT OPINION ON PHARMACOTHERPY, LONDON, UK, 1 January 2008
-WO 2007088019 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; MCCARTHY CLIVE [CH]; PRES) 9 August 2007
 
Examiner: PH. Sultana K. AlOudah

[54] IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS
[57] Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
No. of claims: 11


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.